1795 related articles for article (PubMed ID: 11687119)
41. Velnacrine for Alzheimer's disease.
Birks J; Wilcock GG
Cochrane Database Syst Rev; 2004; (2):CD004748. PubMed ID: 15106259
[TBL] [Abstract][Full Text] [Related]
42. Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials.
Atri A; Frölich L; Ballard C; Tariot PN; Molinuevo JL; Boneva N; Windfeld K; Raket LL; Cummings JL
JAMA; 2018 Jan; 319(2):130-142. PubMed ID: 29318278
[TBL] [Abstract][Full Text] [Related]
43. Rivastigmine for vascular cognitive impairment.
Birks J; McGuinness B; Craig D
Cochrane Database Syst Rev; 2013 May; (5):CD004744. PubMed ID: 23728651
[TBL] [Abstract][Full Text] [Related]
44. Tacrine for Alzheimer's disease.
Qizilbash N; Birks J; López-Arrieta J; Lewington S; Szeto S
Cochrane Database Syst Rev; 2000; 1999(2):CD000202. PubMed ID: 10796507
[TBL] [Abstract][Full Text] [Related]
45. Memantine for dementia.
McShane R; Westby MJ; Roberts E; Minakaran N; Schneider L; Farrimond LE; Maayan N; Ware J; Debarros J
Cochrane Database Syst Rev; 2019 Mar; 3(3):CD003154. PubMed ID: 30891742
[TBL] [Abstract][Full Text] [Related]
46. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group.
Rogers SL; Doody RS; Mohs RC; Friedhoff LT
Arch Intern Med; 1998 May; 158(9):1021-31. PubMed ID: 9588436
[TBL] [Abstract][Full Text] [Related]
47. Vitamin E for Alzheimer's dementia and mild cognitive impairment.
Farina N; Llewellyn D; Isaac MG; Tabet N
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD002854. PubMed ID: 28128435
[TBL] [Abstract][Full Text] [Related]
48. Efficacy and safety of galantamine treatment for patients with Alzheimer's disease: a meta-analysis of randomized controlled trials.
Jiang D; Yang X; Li M; Wang Y; Wang Y
J Neural Transm (Vienna); 2015 Aug; 122(8):1157-66. PubMed ID: 25547862
[TBL] [Abstract][Full Text] [Related]
49. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease.
Rolinski M; Fox C; Maidment I; McShane R
Cochrane Database Syst Rev; 2012 Mar; 2012(3):CD006504. PubMed ID: 22419314
[TBL] [Abstract][Full Text] [Related]
50. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.
Bond M; Rogers G; Peters J; Anderson R; Hoyle M; Miners A; Moxham T; Davis S; Thokala P; Wailoo A; Jeffreys M; Hyde C
Health Technol Assess; 2012; 16(21):1-470. PubMed ID: 22541366
[TBL] [Abstract][Full Text] [Related]
51. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group.
Raskind MA; Peskind ER; Wessel T; Yuan W
Neurology; 2000 Jun; 54(12):2261-8. PubMed ID: 10881250
[TBL] [Abstract][Full Text] [Related]
52. Galantamine: additional benefits to patients with Alzheimer's disease.
Lilienfeld S; Parys W
Dement Geriatr Cogn Disord; 2000 Sep; 11 Suppl 1():19-27. PubMed ID: 10971048
[TBL] [Abstract][Full Text] [Related]
53. Galantamine provides sustained benefits in patients with 'advanced moderate' Alzheimer's disease for at least 12 months.
Blesa R; Davidson M; Kurz A; Reichman W; van Baelen B; Schwalen S
Dement Geriatr Cogn Disord; 2003; 15(2):79-87. PubMed ID: 12566596
[TBL] [Abstract][Full Text] [Related]
54. A prospective, double-blind, community-controlled comparison of three doses of galantamine in the treatment of mild to moderate Alzheimer's disease in a Korean population.
Suh GH; Yeon Jung H; Uk Lee C; Hoon Oh B; Nam Bae J; Jung HY; Ju YS; Kil Yeon B; Park J; Hong I; Choi S; Ho Lee J;
Clin Ther; 2004 Oct; 26(10):1608-18. PubMed ID: 15598477
[TBL] [Abstract][Full Text] [Related]
55. Latrepirdine for Alzheimer's disease.
Chau S; Herrmann N; Ruthirakuhan MT; Chen JJ; Lanctôt KL
Cochrane Database Syst Rev; 2015 Apr; 2015(4):CD009524. PubMed ID: 25897825
[TBL] [Abstract][Full Text] [Related]
56. Cessation versus continuation of galantamine treatment after 12 months of therapy in patients with Alzheimer's disease: a randomized, double blind, placebo controlled withdrawal trial.
Scarpini E; Bruno G; Zappalà G; Adami M; Richarz U; Gaudig M; Jacobs A; Schäuble B
J Alzheimers Dis; 2011; 26(2):211-20. PubMed ID: 21606568
[TBL] [Abstract][Full Text] [Related]
57. Galantamine maintains ability to perform activities of daily living in patients with Alzheimer's disease.
Galasko D; Kershaw PR; Schneider L; Zhu Y; Tariot PN
J Am Geriatr Soc; 2004 Jul; 52(7):1070-6. PubMed ID: 15209643
[TBL] [Abstract][Full Text] [Related]
58. The comparative efficacy and safety of cholinesterase inhibitors in patients with mild-to-moderate Alzheimer's disease: a Bayesian network meta-analysis.
Kobayashi H; Ohnishi T; Nakagawa R; Yoshizawa K
Int J Geriatr Psychiatry; 2016 Aug; 31(8):892-904. PubMed ID: 26680338
[TBL] [Abstract][Full Text] [Related]
59. Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine.
Rodda J; Morgan S; Walker Z
Int Psychogeriatr; 2009 Oct; 21(5):813-24. PubMed ID: 19538824
[TBL] [Abstract][Full Text] [Related]
60. Vitamin E for Alzheimer's dementia and mild cognitive impairment.
Farina N; Llewellyn D; Isaac MGEKN; Tabet N
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD002854. PubMed ID: 28418065
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
